Topics:
ARS 2014|Breast Cancer|Colorectal Cancer|Leukemia & Lymphoma|Lung Cancer|Melanoma|ASCO 2014|Prostate Cancer|Browse All Topics

Breast Cancer

Management of Young Breast Cancer Patients With de Novo Genetic Mutations

A 24-year-old woman presents to her primary care provider with a mass in her left breast. Examination confirms a 2.2-cm mass in the upper outer quadrant, with a single mobile axillary node that is firm to palpation.

Breast Cancer

Benign Breast Mass Not So Benign After All

OBGYN.net Staff
January 16, 2015 | Breast Cancer
By

New evidence reveals that risk prediction for breast cancer is imperative in women with atypical hyperplasia of breast tissue.

The Role of Bisphosphonates in Early- and Advanced-Stage Breast Cancer: Have We Finally Optimized Care?

Phillip S. Blanchette, MSc, MD
Kathleen I. Pritchard, MD, FRCPC
Review Article | January 15, 2015 | Oncology Journal, Breast Cancer
By and

Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia.

Bisphosphonates: Game Changers?

I. Craig Henderson, MD, FACP, FRCP
January 15, 2015 | Oncology Journal, Breast Cancer
By

Bisphosphonates or the monoclonal antibody denosumab, have the potential to profoundly affect the entire metastatic process, not just the growth of bone metastases.

Osteoclast Inhibitors: A Multifaceted Tool in the Management of Breast Cancer

Aki Morikawa MD, PhD
Catherine Van Poznak, MD
January 15, 2015 | Oncology Journal, Breast Cancer
By and

There are still questions to be answered about the use of osteoclast inhibitors in the care of patients with breast cancer. The optimal duration and dosing schedule and how to improve treatment compliance are important issues to address.

Bisphosphonates in Breast Cancer: A Triple Winner?

Aju Mathew, MD, MPhil
Adam Brufsky, MD, PhD
January 15, 2015 | Oncology Journal, Breast Cancer
By and

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.

PIK3CA Mutations Matter in HER2-Positive Breast Cancer

Anna Azvolinsky, PhD
News | January 06, 2015 | HER2-Positive Breast Cancer, Breast Cancer
By

Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.

MRI Improves Breast Cancer Screening in Older BRCA Carriers

Anna Azvolinsky, PhD
News | January 05, 2015 | Breast Cancer, Screening
By

Adding an MRI to a mammogram improved the sensitivity of breast cancer screening in women 50 years of age or older who are BRCA mutation carriers.

Pages

Subscribe to Breast Cancer on [sitename]
View More Videos
View More Podcasts

By clicking Accept, you agree to become a member of the UBM Medica Community.